Published on 27 Feb 2024 on GuruFocus.com via Yahoo Finance
Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results
Net Loss: Reported a net loss of $119.5 million for Q4 and $145.2 million for the full year 2023.Collaboration Revenue: No collaboration revenue for Q4 2023, but a significant increase to $330.5 million for the full year.Research and Development Expenses: R&D expenses rose to $107.8 million for Q4 and $423.9 million for the full year.General and Administrative Expenses: G&A expenses increased to $24.8 million for Q4 and $103.4 million for the full year.Cash Position: Cash, cash equivalents, and marketable securities were approximately $1.03 billion as of December 31, 2023.2024 Guidance: Operating expenses for 2024 anticipated to be less than or equal to those in 2023, with cash runway extending into 2028.
Warning! GuruFocus has detected 2 Warning Sign with DNLI.
Denali Therapeutics Inc (NASDAQ:DNLI) released its 8-K filing on February 27, 2024, detailing its financial results for the fourth quarter and full year ended December 31, 2023. The company, known for its innovative approach to treating neurodegenerative and lysosomal storage diseases, has made significant strides in its therapeutic portfolio and the clinical validation of its blood-brain barrier (BBB) Transport Vehicle (TV) platform.